The management of Heart Failure with Reduced Ejection Fraction (HFrEF) is currently well codified [3] and is based on medical treatment that includes the use of 4 drugs: beta-blockers, angiotensin-converting enzyme inhibitors, sodium-glucose cotransporter 2 inhibitors, and MRAs (Mineralocorticoid Receptor Antagonists). The gene discussed is SLC5A2; the disease is heart failure.